Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
July 23, 2014, 04:32:52 AM

Login with username, password and session length


Members
Stats
  • Total Posts: 631529
  • Total Topics: 47804
  • Online Today: 244
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 4
Guests: 178
Total: 182

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Synthetic Gene Vaccine Trial by Imperial College in Kenya  (Read 662 times)

0 Members and 1 Guest are viewing this topic.

Offline Jmarksto

  • Member
  • Posts: 465
Synthetic Gene Vaccine Trial by Imperial College in Kenya
« on: January 09, 2014, 12:12:15 PM »
http://tinyurl.com/ovxkgh8

An HIV vaccine that uses a synthetic gene to trigger an immune response might offer a way to protect against the virus where others have failed.

Most vaccines work by training immune cells called B-cells to produce antibodies against a virus. Another approach is to stimulate T-cells, which kill cells infected with the virus. This is known as inducing cellular immunity.

Previous T-cell vaccines have largely failed because of HIV's ability to rapidly mutate and escape them.

To get around this, Lucy Dorrell at the University of Oxford and her team created a synthetic gene by stitching together 14 regions of the HIV genome that don't tend to mutate because if they do the virus struggles to survive. This means the vaccine just focuses the immune system on conserved segments, says Dorrell.

Three-pronged approach

To expose the immune system to this gene, it was inserted into three delivery vessels: two disabled viruses and a free-floating circle of DNA called a plasmid. Because vaccines often need to be administered several times to trigger a strong immune response, the hope was that this three-pronged approach would increase the chance that the T-cells would respond to the synthetic gene, even if the B-cells had started to recognise and attack the delivery vessel.

Sure enough, when the three were injected sequentially into healthy people several weeks or months apart, the volunteers produced T-cells specific to many of the 14 regions of HIV some more strongly than others. When these T-cells were added to dishes of the volunteers' own cells that had been infected with HIV in the lab, they stopped the virus replicating.

The team is currently fine-tuning the combination of delivery vessels, but it hopes to begin a second trial in Nairobi, Kenya, in March. This will involve vaccinating people at high risk of contracting HIV to see if it lowers infection rates. All participants will be encouraged to avoid exposing themselves to the virus regardless of whether or not they have received the vaccine.

"The work represents a significant advance in the design of vaccines targeted to induce strong cellular immunity capable of eliminating HIV infected cells" says Robin Shattock of Imperial College London.

Steven Patterson, also at Imperial, agrees that the findings are encouraging but says future research should focus on increasing the magnitude of the response to more of the regions expressed by the synthetic gene. "At this stage, we just do not know whether high responses to one or two conserved [regions] will be sufficient to protect or control virus infection," he says.
03/15/12 Negative
06/15/12 Positive
07/11/12 CD4 790          VL 4,000
08/06/12 CD4 816/38%   VL 49,300
08/20/12 Started Complera
11/06/12 CD4   819/41% VL 38
02/11/13 CD4   935/41% VL UD
06/06/13 CD4   816/41% VL UD
10/28/13 CD4 1131/45%  VL 25
02/25/14 CD4   792/37%  VL UD
07/09/14 CD4 1004/39%   VL UD

Online YellowFever

  • Member
  • Posts: 155
Re: Synthetic Gene Vaccine Trial by Imperial College in Kenya
« Reply #1 on: January 09, 2014, 01:14:32 PM »
Can't they just stick to developing B cell based vaccines? Getting T-cells to fight HIV is like getting a drunkard to work as a bartender...
08/2010 HIV- 08/2012 HIV+
10/2012 CD4 415(15%)
04/2013 CD4 457(15%)
10/2013 CD4 520 (20%) VL 650 (wtf?)
02/2014 CD4 410(20%) VL 390 (yay!)

Offline Ann

  • Administrator
  • Member
  • Posts: 28,134
  • It just is, OK?
    • Num is sum qui mentiar tibi?
Re: Synthetic Gene Vaccine Trial by Imperial College in Kenya
« Reply #2 on: January 09, 2014, 01:18:46 PM »
Can't they just stick to developing B cell based vaccines? Getting T-cells to fight HIV is like getting a drunkard to work as a bartender...

Hey! Some of the best bartenders I've known were drunkards! - Only we call them "piss-heads" here. ;D
Condoms are a girl's best friend

Condom and Lube Info  



"...health will finally be seen not as a blessing to be wished for, but as a human right to be fought for." Kofi Annan

Nymphomaniac: a woman as obsessed with sex as an average man. Mignon McLaughlin

HIV is certainly character-building. It's made me see all of the shallow things we cling to, like ego and vanity. Of course, I'd rather have a few more T-cells and a little less character. Randy Shilts

Offline Jmarksto

  • Member
  • Posts: 465
Re: Synthetic Gene Vaccine Trial by Imperial College in Kenya
« Reply #3 on: January 09, 2014, 01:30:36 PM »
Hey! Some of the best bartenders I've known were drunkards! - Only we call them "piss-heads" here. ;D

I agree, they pour stronger drinks and forget to charge you, although they don't keep secrets very well.

Back to the topic at hand though...many scientific breakthroughs come from very unexpected places we need to try a wide range of approaches.
03/15/12 Negative
06/15/12 Positive
07/11/12 CD4 790          VL 4,000
08/06/12 CD4 816/38%   VL 49,300
08/20/12 Started Complera
11/06/12 CD4   819/41% VL 38
02/11/13 CD4   935/41% VL UD
06/06/13 CD4   816/41% VL UD
10/28/13 CD4 1131/45%  VL 25
02/25/14 CD4   792/37%  VL UD
07/09/14 CD4 1004/39%   VL UD

Offline Ann

  • Administrator
  • Member
  • Posts: 28,134
  • It just is, OK?
    • Num is sum qui mentiar tibi?
Re: Synthetic Gene Vaccine Trial by Imperial College in Kenya
« Reply #4 on: January 09, 2014, 01:35:13 PM »

Back to the topic at hand though...many scientific breakthroughs come from very unexpected places we need to try a wide range of approaches.

I'll drink to that!




(Sorry, couldn't resist! But I do agree, not just being a smartarse.)
Condoms are a girl's best friend

Condom and Lube Info  



"...health will finally be seen not as a blessing to be wished for, but as a human right to be fought for." Kofi Annan

Nymphomaniac: a woman as obsessed with sex as an average man. Mignon McLaughlin

HIV is certainly character-building. It's made me see all of the shallow things we cling to, like ego and vanity. Of course, I'd rather have a few more T-cells and a little less character. Randy Shilts

Offline wolfter

  • Member
  • Posts: 4,340
Re: Synthetic Gene Vaccine Trial by Imperial College in Kenya
« Reply #5 on: January 09, 2014, 01:41:49 PM »
I'll drink to that!




(Sorry, couldn't resist! But I do agree, not just being a smartarse.)

CHEERS!  bottoms up?


OH wait, that's what led me to these forums. ;D
productivity breeds content

Offline Jeff G

  • Administrator
  • Member
  • Posts: 10,705
  • How am I doing Beren ?
Re: Synthetic Gene Vaccine Trial by Imperial College in Kenya
« Reply #6 on: January 09, 2014, 04:25:06 PM »
Miss P will never wear synthetic jeans genes if that's the cure . 

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.